Book
Nanovesicles for the delivery of cardiovascular drugs
| العنوان: | Nanovesicles for the delivery of cardiovascular drugs |
|---|---|
| المؤلفون: | Domenico Marson, Suzana Aulic, Alice Fermeglia, Erik Laurini, Sabrina Pricl |
| المساهمون: | AK Nayak, MS Hasnain, TM Aminabhavi, VP Torchilin, Marson, Domenico, Aulic, Suzana, Fermeglia, Alice, Laurini, Erik, Pricl, Sabrina |
| بيانات النشر: | Academic Press |
| سنة النشر: | 2022 |
| المجموعة: | Università degli studi di Trieste: ArTS (Archivio della ricerca di Trieste) |
| مصطلحات موضوعية: | Nanovesicular delivery system, cardiovascular disease, exosome, liposome, slef-assembling nanovector, nanomedicine |
| الوصف: | Cardiovascular diseases (CVDs) are one of the top causes of death on a global scale. According to the World Health Organization (WHO), 17.9 million people die each year as a result of CVDs. With a focus on Europe, 45% of all fatalities in the “old continent”—37% in the European Union (EU) alone—are attributable to CVDs, globally accounting for 3.9 million annual deaths.2 CVD-related diagnosis and treatment expenses increase at a fast rate and are expected to continue to rise in the next decade. As an example, the EU economic burden is estimated to be around 111 billion Euros for the direct costs of CVD treatments annually, with a 210 billion Euro yearly price tag for overall management of CVDs. This impressive economic load is substantially related to an increase in CVD-associated risk factors, which include, among others, obesity, diabetes, and population aging. Although the application of nanomedicine (NM) in the diagnosis and treatment of CVDs is substantially younger than its oncological counterpart, the rapid pace at which it progresses is testified by the number of laboratory-scale results reported, for example, on PubMed (1853 hits returned for the combined cardiovascular1nanomedicine search performed on May 25, 2021—1111 hits only in the last 5 years). From a historical perspective, the majority of the early CVD-directed nanosystems were produced with the aim to improve bioavailability, stability, and safety of medications that were already on the market. Likely, the first successful example in this respect is represented by the proof-ofprinciple study in which lipid-based nanoparticles (NPs) were engineered to revive the clinical potential of the abandoned CVD-targeting compound wortmannin, a potent inhibitor of phosphatidylinositol 30kinase-related kinases that failed clinical translation due solubility and other drug-delivery challenges.4 According to the design, these NPs had a lipid-polymer surface and a hydrophobic polymeric core in which the hydrophobic drug was incapsulated. A lipid monolayer ... |
| نوع الوثيقة: | book part |
| وصف الملف: | STAMPA |
| اللغة: | English |
| ردمك: | 978-0-323-91865-7 0-323-91865-4 |
| Relation: | info:eu-repo/semantics/altIdentifier/isbn/978-0-323-91865-7; ispartofbook:Applications of nanovesicular drug delivery; firstpage:341; lastpage:370; numberofpages:30; http://hdl.handle.net/11368/3027348; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85142797163; https://www.sciencedirect.com/science/article/pii/B9780323918657000092 |
| DOI: | 10.1016/B978-0-323-91865-7.00009-2 |
| الاتاحة: | http://hdl.handle.net/11368/3027348 https://doi.org/10.1016/B978-0-323-91865-7.00009-2 https://www.sciencedirect.com/science/article/pii/B9780323918657000092 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.F0BEC83C |
| قاعدة البيانات: | BASE |
| ردمك: | 9780323918657 0323918654 |
|---|---|
| DOI: | 10.1016/B978-0-323-91865-7.00009-2 |